Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.

NCT07453836 is registered in ClinicalTrials.gov with China Immunotech (Beijing) Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07453836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07453836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 18, 2026
Completion date
March 18, 2028
Enrollment
13 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia